CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
复发性胶质母细胞瘤的脑室内 CARv3-TEAM-E T 细胞
英文原题：Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma.
查看英文原题
Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
在这项首次人体、研究者发起的开放标签研究中，三名复发性胶质母细胞瘤参与者接受了CARv3-TEAM-E T细胞治疗，这是一种经工程改造的嵌合抗原受体（CAR）T细胞，通过分泌T细胞衔接抗体分子（TEAM），靶向表皮生长因子受体（EGFR）变异体III肿瘤特异性抗原以及野生型EGFR蛋白。CARv3-TEAM-E T细胞治疗未导致大于3级的不良事件或剂量限制性毒性效应。影像学肿瘤消退显著且迅速，在单次脑室内输注后数日内即发生，但三名参与者中有两名的缓解是短暂的。（由Gateway for Cancer Research等资助；INCIPIENT ClinicalTrials.gov编号，NCT05660369。）
展开英文摘要原文
In this first-in-human, investigator-initiated, open-label study, three participants with recurrent glioblastoma were treated with CARv3-TEAM-E T cells, which are chimeric antigen receptor (CAR) T cells engineered to target the epidermal growth factor receptor (EGFR) variant III tumor-specific antigen, as well as the wild-type EGFR protein, through secretion of a T-cell-engaging antibody molecule (TEAM).
Treatment with CARv3-TEAM-E T cells did not result in adverse events greater than grade 3 or dose-limiting toxic effects. Radiographic tumor regression was dramatic and rapid, occurring within days after receipt of a single intraventricular infusion, but the responses were transient in two of the three participants. (Funded by Gateway for Cancer Research and others; INCIPIENT ClinicalTrials. gov number, NCT05660369.) .
论文信息
- 作者
- Choi BD、Gerstner ER、Frigault MJ、Leick MB、Mount CW、Balaj L、Nikiforow S、Carter BS
- 单位
- From the Cellular Immunotherapy Program (B.D.C., M.J.F., M.B.L., C.W.M., K.G., M.V.M.) and Krantz Family Center for Cancer Research (M.B.L., K.G., M.V.M.), Mass General Cancer Center, and the Departments of Neurology (E.R.G.), Pathology (C.W.M., K.G.), Neurosurgery (B.D.C., L.B., B.S.C., W.T.C.), and Medicine (M.J.F., M.B.L., M.V.M.), Massachusetts General Hospital and Harvard Medical School, and Connell and O'Reilly Families Cell Manipulation Core Facility, Dana-Farber/Harvard Cancer Center (S.N.) - both in Boston.United States
- 文献类型
- 美国 NIH 资助研究 · I 期临床试验
- 期刊
- The New England journal of medicine2024 Apr 11
- 原文标识
- PubMed 38477966 · DOI 10.1056/NEJMoa2314390
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →